Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 3 institutions in 1 country.
Mackenzie M Shipley *Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, United States.ORCID 0000-0002-7436-5622
Vidya Mangala Prasad *Department of Medicinal Chemistry, University of Washington, Seattle, United States.
Laura E DoepkerDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, United States.ORCID 0000-0003-4514-5003
Adam DingensDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States.ORCID 0000-0001-9603-9409
Duncan K RalphDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States.
Elias HarkinsDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States.
Amrit DharDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States.
Dana ArenzDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, United States.
Vrasha ChohanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, United States.
Haidyn WeightDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, United States.
Kishor MandaliyaCoast Provincial General Hospital, Women's Health Project, Mombasa, Kenya.
Jesse D BloomDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States.ORCID 0000-0003-1267-3408
Frederick A MatsenDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States.
Kelly K LeeDepartment of Medicinal Chemistry, University of Washington, Seattle, United States.
Julie M OverbaughDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, United States.ORCID 0000-0002-0239-9444
Fred Hutch Cancer Center · USUniversity of Washington · USHoward Hughes Medical Institute · US
Funding
Systems Biology CoreU19AI128914 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Margaret Juliana McElrath, KENNETH D STUART · 2017 to 2026
$29.5M
Modeling the dynamics and evolution of immune responses to influenza virusesU19AI117891 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2015 to 2019
$8.4M
Structural and dynamic traits underlying phenotypic variation in HIV-1 EnvR01AI140868 · NIAID · UNIVERSITY OF WASHINGTON · PI Kelly Keisen Lee · 2019 to 2026
$5.3M
Comprehensive profiling of SARS-CoV-2 antibody responses and escape pathwaysR01AI138709 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2018 to 2022
$5.0M
Blending deep learning with probabilistic mechanistic models to predict and understand the evolution and function of adaptive immune receptorsR01AI146028 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MATSEN, FREDERICK ALBERT · 2019 to 2024
$3.4M
Complete mapping of immune selection from antibodies to HIVR01AI140891 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2019 to 2024
Stimulating broadly neutralizing antibodies (bnAbs) directly from germline remains a barrier for HIV vaccines. HIV superinfection elicits bnAbs more frequently than single infection, providing clues of how to elicit such responses. We used longitudinal antibody sequencing and structural studies to characterize bnAb development from a superinfection case. BnAb QA013.2 bound initial and superinfecting viral Env, despite its probable naive progenitor only recognizing the superinfecting strain, suggesting both viruses influenced this lineage. A 4.15 Å cryo-EM structure of QA013.2 bound to native-like trimer showed recognition of V3 signatures (N301/N332 and GDIR). QA013.2 relies less on CDRH3 and more on framework and CDRH1 for affinity and breadth compared to other V3/glycan-specific bnAbs. Antigenic profiling revealed that viral escape was achieved by changes in the structurally-defined epitope and by mutations in V1. These results highlight shared and novel properties of QA013.2 relative to other V3/glycan-specific bnAbs in the setting of sequential, diverse antigens.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. · full record | OpenQuestion